Form Type: 4

SEC EDGAR Link
Accession Number:0000899243-21-035221
Date:2021-09-01
Issuer: GLOBAL BLOOD THERAPEUTICS, INC. (GBT)
Original Submission Date:

Reporting Person:

FARROW JEFFREY S
C/O GLOBAL BLOOD THERAPEUTICS, INC.
181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO, CA 94080

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-09-01 M 2,762 a $0.00 22,830 direct
COMMON STOCK 2021-09-01 F 1,370 d $29.85 21,460 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
RESTRICTED STOCK UNITS 0.0 2021-09-01 deemed execution date M 2,762 (d) common stock 2,762 $0.00 19,340 direct
Footnotes
IDfootnote
f1 each restricted stock unit ("rsu") represents the right to receive one share of the issuer's common stock.
f2 represents number of shares of issuer's common stock withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,762 shares of common stock underlying the reporting person's rsus.
f3 the shares of common stock underlying the rsus vest in 8 equal semi-annual installments over 4 years from march 1, 2021, so long as the reporting person continues as an employee or other service provider of the issuer through each vesting date. the rsus are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the issuer.

Elevate your investments